1 – 2 of 2
      - show: 10
- |
- sort: year (new to old)
        Close
        
            
    
    Embed this list
<iframe src=""
              width=""
              height=""
              allowtransparency="true"
              frameborder="0">
            </iframe>
        - 2025
- 
                        Mark
        CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer : Biomarkers associated with outcomes from OPTIMIZE-1
    (2025) In Cell Reports Medicine- Contribution to journal › Article
 
- 2024
- 
                        Mark
        Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1) : a single-arm, multicentre phase 1b/2 study
    
    - Contribution to journal › Article